Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
Havrdova, Eva
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. [electronic resource] - Expert opinion on pharmacotherapy Oct 2013 - 2145-56 p. digital
Publication Type: Journal Article; Comment
1744-7666
10.1517/14656566.2013.826190 doi
Female
Fumarates--therapeutic use
Humans
Immunosuppressive Agents--therapeutic use
Male
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Peptides--therapeutic use
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. [electronic resource] - Expert opinion on pharmacotherapy Oct 2013 - 2145-56 p. digital
Publication Type: Journal Article; Comment
1744-7666
10.1517/14656566.2013.826190 doi
Female
Fumarates--therapeutic use
Humans
Immunosuppressive Agents--therapeutic use
Male
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Peptides--therapeutic use